Tharimmune (Tharimmune) Short Interest

View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Tharimmune's Short Interest

For the Biotechnology subindustry, Tharimmune's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tharimmune's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tharimmune's Short Interest distribution charts can be found below:

* The bar in red indicates where Tharimmune's Short Interest falls into.

Tharimmune (Tharimmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807

Website

https://www.hillstreambio.com

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors.

Executives

Randy Milby	director, officer: Chief Executive Officer	5 JACK LANE, NEWARK DE 19711
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur	director	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas	10 percent owner	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess	officer: Chief Financial Officer	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Sireesh Appajosyula	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Lynne A. Bui	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc	10 percent owner	16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc	10 percent owner	179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807